Real-world studies no substitute for RCTs in establishing efficacy
- 1 January 2019
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 393 (10168) , 210-211
Abstract
No abstract availableFunding Information
- AstraZeneca
- Boehringer Ingelheim
- Bayer
- Janssen Pharmaceutica
- GlaxoSmithKline
- Merck Sharp and Dohme United Kingdom
- Johnson and Johnson
- Novo Nordisk
- Pfizer
- Novartis
- Bristol-Myers Squibb
- Eli Lilly and Company
- Abbott Laboratories
- Amgen
- Merck
This publication has 9 references indexed in Scilit:
- Improving observational studies in the era of big dataThe Lancet, 2018
- Association is not causation: treatment effects cannot be estimated from observational data in heart failureEuropean Heart Journal, 2018
- SGLT-2 Inhibitors and Cardiovascular RiskJACC, 2018
- ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetesAmerican Heart Journal, 2018
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert ForumDiabetes Care, 2017
- When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?Clinical Pharmacology & Therapeutics, 2017
- Sensitivity Analysis in Observational Research: Introducing the E-ValueAnnals of Internal Medicine, 2017
- Second line initiation of insulin compared with DPP-4 inhibitors after metformin monotherapy is associated with increased risk of all-cause mortality, cardiovascular events, and severe hypoglycemiaDiabetes Research and Clinical Practice, 2017
- Basal Insulin and Cardiovascular and Other Outcomes in DysglycemiaNew England Journal of Medicine, 2012